Aerie Pharmaceuticals Inc. (NASDAQ:AERI) had its target price raised by equities researchers at Stifel Nicolaus to $55.00 in a report released on Thursday. Stifel Nicolaus’ price target points to a potential upside of 40.09% from the company’s current price.
A number of other research analysts have also commented on the company. Brean Capital reissued a “buy” rating and set a $63.00 price objective on shares of Aerie Pharmaceuticals in a report on Thursday. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. HC Wainwright assumed coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 20th. They set a “buy” rating and a $66.00 target price for the company. RBC Capital Markets restated an “outperform” rating and set a $55.00 target price (up previously from $51.00) on shares of Aerie Pharmaceuticals in a research note on Friday, September 16th. Finally, Canaccord Genuity set a $50.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, September 14th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $51.40.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at 39.26 on Thursday. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $41.72. The company’s market capitalization is $1.10 billion. The company’s 50-day moving average price is $27.34 and its 200-day moving average price is $19.13.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.02. On average, equities analysts forecast that Aerie Pharmaceuticals will post ($2.80) EPS for the current fiscal year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The stock was acquired at an average price of $17.50 per share, for a total transaction of $4,375,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 8.77% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of AERI. Jennison Associates LLC boosted its stake in Aerie Pharmaceuticals by 0.6% in the second quarter. Jennison Associates LLC now owns 3,711,695 shares of the company’s stock worth $65,326,000 after buying an additional 21,505 shares in the last quarter. Deerfield Management Co. boosted its stake in Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock worth $32,011,000 after buying an additional 1,824,607 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $36,960,000 after buying an additional 75,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Aerie Pharmaceuticals by 11.1% in the second quarter. Vanguard Group Inc. now owns 1,006,552 shares of the company’s stock worth $17,716,000 after buying an additional 100,645 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Aerie Pharmaceuticals by 10.5% in the second quarter. BlackRock Fund Advisors now owns 971,896 shares of the company’s stock worth $17,105,000 after buying an additional 92,113 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.